1. Mortality risk prediction of high-sensitivity C-reactive protein in suspected acute coronary syndrome: A cohort study
- Author
-
Kaura, Amit, Hartley, Adam, Panoulas, Vasileios, Glampson, Ben, Shah, Anoop S. V., Davies, Jim, Mulla, Abdulrahim, Woods, Kerrie, Omigie, Joe, Shah, Anoop D., Thursz, Mark R., Elliott, Paul, Hemmingway, Harry, Williams, Bryan, Asselbergs, Folkert W., O'Sullivan, Michael, Lord, Graham M., Trickey, Adam, Sterne, Jonathan AC, Haskard, Dorian O., Melikian, Narbeh, Francis, Darrel P., Koenig, Wolfgang, Shah, Ajay M., Kharbanda, Rajesh, Perera, Divaka, Patel, Riyaz S., Channon, Keith M., Mayet, Jamil, and Khamis, Ramzi
- Subjects
Mortality -- Risk factors ,Acute coronary syndrome -- Prognosis -- Patient outcomes ,C-reactive protein -- Measurement -- Health aspects ,Biological sciences - Abstract
Background There is limited evidence on the use of high-sensitivity C-reactive protein (hsCRP) as a biomarker for selecting patients for advanced cardiovascular (CV) therapies in the modern era. The prognostic value of mildly elevated hsCRP beyond troponin in a large real-world cohort of unselected patients presenting with suspected acute coronary syndrome (ACS) is unknown. We evaluated whether a mildly elevated hsCRP (up to 15 mg/L) was associated with mortality risk, beyond troponin level, in patients with suspected ACS. Methods and findings We conducted a retrospective cohort study based on the National Institute for Health Research Health Informatics Collaborative data of 257,948 patients with suspected ACS who had a troponin measured at 5 cardiac centres in the United Kingdom between 2010 and 2017. Patients were divided into 4 hsCRP groups ( Following the exclusion criteria, there were 102,337 patients included in the analysis (hsCRP 15 mg/L makes it unlikely that sepsis was a major contributor. Conclusions These multicentre, real-world data from a large cohort of patients with suspected ACS suggest that mildly elevated hsCRP (up to 15 mg/L) may be a clinically meaningful prognostic marker beyond troponin and point to its potential utility in selecting patients for novel treatments targeting inflammation. Trial registration ClinicalTrials.gov - NCT03507309, Author(s): Amit Kaura 1,2, Adam Hartley 1,2, Vasileios Panoulas 1,2, Ben Glampson 2, Anoop S. V. Shah 1,2,3, Jim Davies 4, Abdulrahim Mulla 2, Kerrie Woods 4, Joe Omigie 5, [...]
- Published
- 2022
- Full Text
- View/download PDF